explore -WSS

explore

author：hotspot 2025-09-29 19:58:44 - browse：12259

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Stanford president to resign after investigation of research

knowledge

focus

WSS

India sets sights on home

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

TikTok cracks down on users posting about weight loss drugs

AI can decode, harness the power of the humane immune system

The future of health care in the House

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

entertainment

explore

focus

At least 13 dead in Texas as scorching temps continue

The future of health care in the House

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Man who had jail sentence commuted by Trump arrested again

23andMe had bad news about my health. I wish a person had delivered it

Seattle police shoot person suspected in downtown stabbing

Heart attack and stroke risk calculators need revising

Lindsay Lohan welcomes 1st child with husband Bader Shammas

United colonoscopy coverage change 'may cost lives,' doctors say

New warning issued for rebooking air travel after delays, cancellations

knowledge

Stanford president to resign after investigation of research

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Ebola public health emergency is over, WHO declares

'Reaching a detente': STAT's Helen Branswell on covering Covid

Celebrate National Dole Whip Day for 3 days this week at Disney

The future of health care in the House

knowledge

focus

explore

explore